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Abstract 
Aim: The pathophysiology of insulin resistance (IR) comprises a complex adipokine mediated 
cross-talk between white adipose tissue and other organs. Dipeptidyl peptidase-4 (DPP4) is 
protease recently proposed as a novel adipokine linked to IR. We aimed to assess the 
relationship between fasting serum DPP4 activityand IR in type 1 diabetic (T1DM) patients. 
Methods: A cross-sectional study comprised 44 T1DM patients aged >18 and <65 years. IR 
was esimated using the equation for insulin sensitivity derived from euglycemic-
hyperinsulinemic clamp studies-estimated glucose disposal rate (eGDR). DPP4 serum activity 
was determined spectrophotometrically as a rate of cleavage of 7-Amino-4-Methyl  Coumarin 
(AMC) from H-Gly-Pro-AMC. 
Results: Patients were divided according to DPP4 activity tertiles (<25.40; ≥36.54 U/L). 
Fasting serum DPP4 activity was related to disease duration (p=0.012), systolic (p=0.009) and 
diastolic (p=0.047) blood pressure, waist circumference (p=0.037), urine albumin excretion 
(p=0.022) and conversely related to eGDR (p=0.004). The linear regression has shown that 
eGDR decreases for 0.203 mgkg
-1
min
-1
 by each increase of serum DPP4 activity of 1 U/L 
(p<0.001) after adjustment for adjusted for age, gender, disease duration, albuminuria and the 
use of antihypertensives and statins. 
Conclusion: Serum DPP4 activity is associated with IR in T1DM patients and it might play an 
important role in its pathophysiology. 
Key words: dipeptidyl peptidase-4, insulin resistance, type 1 diabetes 
1. Introduction 
Insulin resistance (IR) is an inability of insulin to produce its actions in peripheral tissue 
derived either from interference of insulin binding to its surface receptor or by impairment of 
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insulin signalization distal from the cell surface [1-3]. Although IR typically characterise type 
2 diabetes mellitus (T2DM), while the insulin deficiency is considered as a primary defect in 
type 1 diabetes mellitus (T1DM), a consistent body of literature suggests that there is a certain 
degree of IR in patients with T1DM [4, 5]. The mechanisms of IR in T1DM is likely due to a 
combination of supraphysiologic levels of exogenous insulin and obesity. In the past, it was 
thought that IR in T1D was primarily related to hyperglycemia [6]. It was recently proposed 
that adults with T1DM have both impaired glucose utilization and impaired insulin-induced 
non-esterified fatty acid suppression, independent of glycemic control [7]. Skeletal muscle IR 
is a known feature of T1DM and is due to decreased glucose transport into myocytes from 
impaired insulin-stimulated upregulation of GLUT4 transporter [8]. White adipose tissue has 
been recognized as major endocrine organ producing a huge diversity of adipokines which 
build a complex inter- and intra- cellular feedback loops that could link obesity to IR [9, 10]. 
Lamers et al. (2011) [11] have performed a comprehensive proteomic profiling of the media 
derived from primary human adipocytes and proposed dipeptidyl peptidase-4 (DPP4) as a 
novel adipokine linking adipose tissue to  IR. 
DPP4 is a serine exopeptidase also known as adenosine desaminase complexing protein 2 
(ADCP 2) or T-cell activation antigen CD26 which cleaves X-proline dipeptides from the N-
terminus polypeptides such as chemokines, neuropeptides and peptide hormones [12]. It exists 
in two forms: as an integral membrane glycoprotein expressed ubiquitously on the cell surface 
and in a soluble form in the circulation. A fraction of soluble DPP4 originates from the 
immune system cells which explains its altered abundance and the circulating activity in 
various immune mediated conditions [13] although the major source of soluble DPP4 fraction 
remains unknown. Since T1DM is an immune mediated condition, the reports on elevated 
DPP4 activity in serum is not suprising [14]. The data from two independent studies suggest 
that DPP4 activity is higher in patients with T1DM compared to healthy controls but 
 4 
independently of islet-cell antibody status, C-peptide level, disease duration or glycated 
haemoglobin (HbA1c) level [14, 15] However, they do report an inverse correlation with 
body mass index and insulin sensitivity [15]. Serum DPP4 activity is also higher in T2DM 
individuals with IR compared to those without [16]. DPP4 is highly expressed on kidney cell 
surface and data are available to suggest that DPP4 levels may associated with of renal 
function [17]. Moreover, insulin sensitivity, assessed by hyperinsulinemic-euglycemic clamp, 
is continuously associated with a greater risk of increasing albuminuria [18]. Accordingly, the 
aim of this study was to investigate relationship between fasting serum DPP4 activity, insulin 
resistance and renal function in T1DM patients. 
 
2. Subjects 
This cross-sectional was study undertaken at the University Clinic for diabetes, endocrinology 
and metabolic diseases Vuk Vrhovac (Zagreb, Croatia). We recruited 44 T1DM C-peptide 
negative (C-peptide <0.3 ng/mL) patients aged >18 and <65 years comming for their 
comprehensive annual review. The sample size was in accordance with G power 3.1.7 
calculation for correlations (two tailed t test, total sample size=44, α=0.05, 1-β=0.8, ρ=0.4). 
The diagnosis of T1DM was defined as suggested by American Diabetes Association 
guidlines from the year 2010 [19]. The inclusion criteria were: age at onset of diabetes 
younger than 40 years, positive autoantibodies and time to definite insulin therapy less then a 
year. Non inclusion criteria were: medical history of cardiovascular diseases or 
electrocardiogram (ECG) evidence of ischemic heart disease, any systemic disease and any 
infection in the previous month, thyroid hormone therapy, medications that might affect 
glucose metabolism and insulin sensitivity such as glucocorticoids or oral contraceptives. The 
study subjects could be using antihypertensive or lipid lowering drugs (i.e., statins: 
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atorvastatin and simvastatin). The study was conducted according to the guidelines laid down 
in the Declaration of Helsinki. Written informed consent was obtained from and signed by all 
patients. 
 
2.1 Subjects and Methods 
Insulin sensitivity was calculated using the equation derived from euglycemic-
hyperinsulinemic clamp studies, estimated glucose disposal rate (eGDR): 24.31–
12.2X(WHR)–3.29X(AHT)–0.57X(HbA1c), where the units are mgkg–1min–1, WHR 
indicates the waist to hip ratio, AHT indicates blood pressure, and is expressed as: 0-no, 1-
yes. Those on blood pressure medications or with blood pressure >140/90 mmHg were 
considered to have hypertension the equation was derived from a substudy of 24 EDC 
(Epidemiology of Diabetes Complications) participants who underwent euglycemic-
hyperinsulinemic clamp studies [20]. Lower eGDR levels indicate greater insulin resistance.  
2.2 Laboratory analysis 
The detailed description of the methods concerning anthropometric measurement and 
standard laboratory procedurs was conducted as previously described [21]. Fasting venous 
blood samples were collected for the determination of biochemistry panel, lipid profile status, 
glycated haemoglobin A1c (HbA1c) and serum DPP4 activity. After clotting, the sera were 
separated and kept at −70°C until the determination of enzymatic activity. Urin albumin 
excretion (UAE) was measured from at least two 24-h urine samples and determined as the 
mean of 24-h urine collections and expressed as mg/24h. Patients performed collections on 
two consecutive days to minimize variability. Data on serum creatinine levels, age, sex and 
race were used to calculate the estimated GFR (eGFR) using the Chronic Kidney Disease 
Epidemiology Collaboration (CKD-EPI) formula, which has been shown to be accurate in 
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determining renal function in diabetic patients with normal renal function [22, 23]. DPP4 
activity was measured by a colorimetric assay procured from Sigma, St. Louis, MO, USA in a 
microplate reader (Cary Eclipse Varian, Agilent Technologies) at 460 nm, 37⁰C in a 
continuous monitoring for 35 minutes. In this assay, DPP4 cleaves H-Gly-Pro-AMC to 
release a florecent product, 7-Amino-4-Methyl  Coumarin (AMC) which can be measured 
spectrophotometrically.  All the DPP4 assays were run in duplicates. Briefly, 50 μL of serum 
sample was added to 96-well plates, followed by the addition of 10 μL assay buffer. After 10 
min of pre-incubation at 37⁰, the enzymatic reaction was started with the addition of 40 μL of 
Master Reaction Mix containing 2 μL substrate and 38 μL of the assay buffer. Liberation of 
AMC was monitored continuously at excitation 360 nm and emission 460 nm every 5 min for 
up to 35 min in a 96-well black flat bottom plate. Fluorometric catalysis rates were 
determined from the linear portion of the curve of the increase in fluorescence and were 
calculated as the slope of the regression line determined from the line. DPP4 was expressed as 
pmole/min/mL (U/L). One unit of activity was defined as the amount of enzyme which will 
hydrolize the DPP4 substrate to yiled 1.0 µmole of AMC per minute at 37⁰C. 
 
2.3 Data analysis and Statistics 
The data distribution was assessed by Shapiro-Wilk test. All the continuous variables were 
log-transfrormed and reported as mean values and 95%CI of means, whereas categorical 
variables were reported as numbers and percentages. Because we found normal distribution of 
the data, the differences between three study groups were tested by one-way ANOVA 
followed by Bonferroni’s correction for multiple comparisons while the categorical variables 
were analysed by the χ2 test. Correlations between fasting serum DPP4 activity with 
anthropometric and metabolic variables were determined using Pearson’s correlation 
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coefficient. All the tests were two-sided. The association between fasting serum DPP4 activity 
and eGDR value was further evaluated in multivariate linear regression. Adjustments were 
performed for age, gender, disease duration, eGFR, UAE, the use of statins and 
antihypertensive agents since it is yet to be clarified whether they affect serum DPP4 activity. 
Level of statistical significance was chosen to be 0.05. Statistical analysis was performed by 
Statistical Package for the Social Sciences (SPSS) ver. 17.0 and MedCalc 11.0 for Windows. 
 
3. Results 
The clinical and biochemical characteristics of all 44 T1DM patients are given in Table 1. Out 
of 44 study participants, 28 (63.6%) were male, mean age approximately 45 years and 21 
years of diabetes duration. Thirty patients (68.2%) were using statins and 22 (50%) 
antihypertensive agents, i.e. angiotensin-converting enzyme inhibitors (ACEI). Patients were 
divided into three groups according to the tertiles (25
th
, 50
th
 and 75
th
) of fasting serum DPP4 
activity. The detailed clinical and laboratory findings and the difference between them are 
given in Table 2. The group of patients in the 1
st
 tertile of fasting serum DPP4 activity had 
significantly shorter disease duration (p=0.012), lowest systolic (p=0.009) and diastolic 
(p=0.047) blood pressure, waist circumference (p=0.037) and UAE (p=0.022)compared to 
second and third tertile. The eGDR was significantly higher in the group with lowest serum 
DPP4 activity compared to tertiles with higher DPP4 activity (p=0.004). The groups also 
showed significant difference in the statins use (7 (46.6%) vs 10 (66.6%) vs 13 (92.8%), 
p<0.001). Fasting serum DPP4 activity showed positive correlation with age (r=0.321, 
p=0.034), systolic blood pressure (r=0.423, p=0.004), UAE (r=0.279, p=0.014) anddisease 
duration (r=0.474, p=0.001) while negative correlation with eGDR (r=-0.612, p<0.001). The 
simple linear regression with eGDR as dependent variable has shown that eGDR significantly 
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decreases for 0.221 mgkg
-1
min
-1
 for each increase of serum DPP4 activity of 1 U/L (p<0.001) 
in the unadjusted model and for 0.155 mgkg
-1
min
-1
 after adjustment for the possible 
confounders (age, gender, disease duration, UAE and eGFR and the use of ACEI agents as 
well as statins) (Table 3.).  
4. Discussion 
We assessed metabolic variables, insulin sensitivity and renal function parameters in three 
groups of T1DM patients according to the mean values of fasting serum DPP4 activity. The 
group of patients with highest DPP4 activity had the lowest insulin sensitivity after 
controlling for all possible factors affecting DPP4 serum activity [15]. There are only several 
reports on serum DPP4 activity in T1DM, with one study reporting a significant correlation 
between serum DPP4 activity and HbA1c [24] and another suggesting the opposite [14]. We 
could neither confirm or reject the correlation between serum DPP4 activity and HbA1c since 
the group of patients in the second tertile had highest HbA1c but the difference did not reach 
statistical significance. Furthermore, Varga et al. (2010.) [16] determined serum DPP4 
activity at fasting sate and after test meal in 41 T1DM, 87 T2DM patients and in 25 healthy 
volunteers. Serum DPP4 activity was significantly higher both in fasting and postprandial 
state in patients with T1DM than in T2DM and control subjects irrespective of HbA1c or 
fasting serum glucose. Those results suggest that the type of diabetes might be an important 
factor in DPP4 activity determination.  
Since T1DM is an autoimmune disease, we can hypothesise that elevated serum DPP4 
activity might be attributable to variety of inflammatory reactions leading to pancreatic β cell 
destruction. Despite, two independent studies indicate that serum enzyme activity is not 
affected by islet-cell or glutamic acid decarboxylase antibodies [14, 15]. Here we found 
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significantly higher DPP4 activity in subjects with longer disease duration. We speculate that 
DPP4 activity is correlated with long term exposure to a high glucose concentration.  
Similar to Iwabuchi et al. (2013) [15] we found no correlation between enzyme activity in 
serum and BMI, although the BMI was slightly higher in the third tertile. The measurements 
of central obesity, i.e. waist circumference and waist-to-hip ratio were significantly higher in 
the same group. That is in accordance with the well established fact that visceral adipose 
tissue is the key player in cytokine dysregulation leading to IR [5, 25]. Lamers et al. (2011) 
[11] suggested that both cell surface resident and soluble DPP4 provide multiple autocrine 
and paracrine functions resulting in IR and MS since although they did not assess the DPP4 
enzymatic activity but its concentration. They showed that DPP4 treatment of primarily 
human adypocites, skeletal and smooth muscle cells results in a dose-dependent decrease in 
insulin-stimulated Akt phosphorylation, one of the key players in intracellular insulin 
signalling pathways [26] which clearly referees to DPP4 enzymatic activity and not 
concentration. In addition, they also demonstrated negative correlation of DPP4 serum 
concentration with adiponectin levels which was further confirmed regarding the DPP4 serum 
activity [15]. Adiponectin is already described as a factor that might play a protective role on 
IR development in general [27], as well as in T1DM population [21]. Furthermore, we also 
demonstrated that systolic and diastolic blood pressure are lowest in the first tertile and that 
systolic blood pressure correlates positively with enzymatic activity. With respect to this and 
the recent data on high expression of this enzyme in the kidney [17] there is a possibility that 
kidney function may play a role in DPP4 serum activity. Following the data interpretation in 
the light of indexes of kidney function, DPP4 serum activity remained independently 
associated with lower insulin sensitivity. In support to our study results, Yang et al. (2014) 
[28] have recently demonstrated that DPP4 activity is significantly higher in healthy subjects 
with higher blood pressure and insulin resistance determinated by HOMA-IR index in 
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apparently healthy Chinese man and woman. Recent experimental and clinical studies suggest 
that DPP4 inhibition reduces blood pressure [29] although the underlying mechanism remains 
poorly understood. Currently, there are evidence that DPP4 inhibition leads to increased 
nitric-oxide (NO) bioavailability but the question whether the it occurs in a direct or indirect 
pathway indicating the potential role of DPP4 substrates, especially via glucagon-like peptide-
1 (GLP-1) receptor [30, 31].  
Our study has several limitations that should be pointed out: the sample size was too small to 
derivate any general conclusions, the insulin sensitivity was not assessed by a euglycemic 
clamp which is a gold standard in insulin sensitivity determination and we did not measure 
any DPP4 substrates in the circulation. It is expected that if the serum DPP4 activity is 
increased there should be changes in the circulating levels of a number of substrates of DPP4. 
However, we recently found that the circulating GLP-1 is lower in T1DM population with 
higher IR compared to those without as well as when compared to healthy population [32] 
which could partially explain this study results since the inclusion criteria were the same. 
Despite, we can conclude that serum DPP4 activity may be a surrogate marker of IR in T1DM 
patients or that it might play an important role in its pathophysiology. However, it is possible 
that DPP4 might activate inflammatory response resulting in IR or that serum DPP4 activity 
may be secondary to diabetic nephropathy rather than IR per se which cannot be accessed 
from s single, small-group cross-sectional study. Further investigation with comprehensive 
evaluation of insulin sensitivity in a larger sample are warranted to elucidate the role soluble 
DPP4 activity in IR development, based on the present study results, DPP4 inhibition might 
offer an alternative therapeutical approach  in T1DM offering a potential protective effect in 
metabolic deterioration in T1DM population.  
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Table 1. Clinical characteristics and the fasting serum DPP-4 activities of type 1 diabetic 
patients with mean values indicated in bold letters and (95% Confidence Intervals of means 
indicated in parenthesis) or absolute numbers in bold letters (and percentages in parenthesis) 
Age (years) 45,36 (41,47 - 49,26) 
Gender (male, n (%)) 28               (63.6%) 
Diabetes duration (years) 23,71 (20,42 - 26,99) 
HbA1c (%) 7,4 (7,1 - 7,7) 
BMI (kg/m2) 25,93 (24,98 - 26,88) 
Waist circumference (cm) 89,29 (86,02 - 92,57) 
WHR 0,883 (0,859 - 0,907) 
Systolic blood pressure (mmHg) 128,97 (124,09 - 133,86) 
Dyastolic blood pressure (mmHg) 80,91 (78,59 - 83,24) 
Total cholesterol (mmol/L) 4,9 (4,7 - 5,2) 
HDL cholesterol (mmol/L) 1,59 (1,51 - 1,69) 
HDL2 (mmol/L) 0,49 (0,44 - 0,54) 
HDL3 (mmol/L) 1,11 (1,03 - 1,18) 
LDL cholesterol (mmol/L) 2,85 (2,61 - 3,09) 
TG (mmol/L) 1,09 (0,97 - 1,23) 
VLDL cholesterol (mmol/L) 0,51 (0,45 - 0,56) 
DPP4 activity (U/L) 31,42 (29,68 - 33,15) 
eGDR (mgkg-1min-1) 7,11 (6,47 - 7,73) 
UAE (mg/24h) 63,41 (4,97-121,85) 
 
Legend: eGFR:estimated glomerular filtration rate; eGDR:estimated glucose disposal rate; UAE:urian 
albumin excretion 
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Table 2. Clinical and laboratory characteristics according to the fasting serum DPP-4 activity 
tertiles (<25.40 U/L; ≥36.54 U/L) of type 1 diabetic patients with mean values indicated in 
bold letters and (95% Confidence Intervals of means indicated in parenthesis) or absolute 
numbers in bold letters (and percentages in parenthesis) 
  Percentiles of DPP4 activity (U/L) 
  
  
25
th
 
n=15 
50
th  
n=15 
75
th 
n=14 
Mean 95% CI Mean 95% CI Mean 95% CI 
DPP4 activity (U/L)* 24.66  
 
23.52-25.82 32.38 31.05-33.69 37.62 36.87-38.86 
Age (years)* 42,13 35,09 - 49,17 40,87 33,35 -
 48,38 
53,64 49,09 - 58,19 
Gender (male, N 
(%)) 
11 (73.3%) 6 (40%) 11 (78.6%) 
Diabetes duration 
(years)* 
18,53 13,44 - 23,63 22,87 17,45 -
 28,28 
30,14 23,88 - 36,41 
Fasting plasma 
glucose (mmol/L) 
6,4  5,2 - 7,5 6,7  5,6 - 7,8 9,3  6,8 - 11,7 
HbA1c (%) 6,9 6,5 - 7,5 8,1 7,1 - 9,1 7,4 6,9 - 7,9 
BMI (kg/m
2
) 25,53 24,39 - 26,68 25,93 23,69 -
 28,17 
26,36 24,55 - 28,16 
Total daily insulin 
requirement (U/kg) 
0,615  0,508 - 0,722 0,651  0,563 - 
0,740 
0,657  0,564 - 0,749 
Waist circumference 
(cm)* 
86,47 79,37 - 93,57 90,43 84,53 -
 96,33 
91,07 86,08 - 96,05 
Waist-to-height-
ratio* 
0,855 0,814 - 0,896 0,888 0,850 -
 0,925 
0,908 0,858 - 0,958 
Systolic blood 
pressure* (mmHg) 
119,67 114,28 -
 125,05 
131,67 122,33 -
 141,01 
136,07 126,39 -
 145,79 
Diastolic blood 
pressure (mmHg)* 
77,33 74,59 - 80,08 82,50 77,34 -
 87,66 
83,00  78,71 - 87,29 
Total cholesterol 
(mmol/L) 
4,73 4,34 - 5,14 4,99 4,59 - 5,37 5,24 4,64 - 5,83 
HDL cholesterol 
(mmol/L)* 
1,75 1,54 - 1,96 1,52 1,38 - 1,65 1,51 1,41 - 1,62 
LDL cholesterol 
(mmol/L) 
2,53 2,16 - 2,91 2,96 2,57 - 3,35 3,07 2,51 - 3,63 
VLDL cholesterol 
(mmol/L) 
0,47 0,39 - 0,58 0,52 0,40 - 0,63 0,56 0,46 - 0,68 
Triglycerides 
(mmol/L) 
1,04 0,84 - 1,29 1,13 0,87 - 1,38 1,21 0,99 - 1,48 
eGDR (mgkg-1min-
1)* 
8,487 7,228 - 9,747 6,932 5,995 -
 7,868 
5,796 5,129 - 6,463 
UAE (mg/24h)* 8,15 4,92-13,41 11,99 5,23-27,14 20,36 7,35-56,39 
Legend: *p<0.05; eGFR:estimated glomerular filtration rate; eGDR:estimated glucose disposal rate; 
UAE:urian albumin excretion 
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Table 3. Linear regression analysis for the serum DPP4 activity (U/L) and the eGDR (mgkg
-
1
min
-1
) derived from five separate models 
Model      B    
p 
value 
95,0% Confidence 
Interval for B 
Lower 
Bound 
Upper 
Bound 
 
Serum Dpp4 activity (U/L) 
 
-0.221  <0.001 -0.331 -0.132 
Serum Dpp4 activity (U/L) adjusted for age and 
gender 
 
-0.219 <0.001 -0.303 -0.135 
Serum Dpp4 activity (U/L) adjusted for age, gender 
and disease duration  
 
-0.223 <0.001 -0.313 -0.133 
Serum Dpp4 activity (U/L) adjusted for age, gender, 
disease duration and the use of statins 
 
-0.156 0.005 -0.265 -0.047 
Serum Dpp4 activity (U/L) adjusted for age, gender, 
disease duration, the the use of statins and the use of 
antihypertensive agents (i.e. ACEI) 
 
 
 
 
-0.155 0.007 -0.264 -0.046 
 
Serum Dpp4 activity (U/L) adjusted for age, gender, 
disease duration, the the use of statins, UAE, eGFR 
and the use of antihypertensive agents (i.e. ACEI) 
 
-0,203  <0.001 -0,298 -0,108 
Legend: UAE-urine albumin excretion; eGFR-estimated glomerular filtration rate 
 
 
 
 
